Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like This is the Fastest Growing Cancer Biotech No One Really Knows About July 12, 2017 Unfavorable Ruling Forces Acorda to Pink Slip 20% of Jobs April 4, 2017 What Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets June 26, 2017
